Simplify Logo

Full-Time

Associate Director

Business Systems

Posted on 5/20/2024

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Expert

Boston, MA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree with 10+ years of relevant work experience supporting enterprise systems, preferably in a biotech/pharma organization. Equivalent work experience will be considered
  • Experience with Microsoft Office 365, R&D Systems, and enterprise document management systems (Egnyte, Veeva, etc.)
  • Demonstrated experience in solution design and enterprise architecture, with focus on scalability and automation
  • Must be knowledgeable of server class hardware and network infrastructure best practices
  • Ability to analyze financial and technical data to support the development and implementation of technological solutions for distinct business units
  • Ability to manage projects simultaneously, manage conflicting priorities, and be flexible when priorities change
  • Ability to manage, mentor, and direct the personal development of staff
  • Demonstrate excellent leadership and communication skills
  • Demonstrate strong organizational skills, including the ability to prioritize
  • Experience working in a pharma/biotech environment on FDA/GxP-validated systems, including 21 CFR Part 11 and applicable regulations, guidance, and compliance requirements related to computerized systems
  • Experience with ensuring IT systems and processes comply with other regulations such as SOX, GDPR, HIPAA, and other regulations as applicable
Responsibilities
  • You will maintain the current Information Architecture and implement accompanying infrastructure to support the digital strategy
  • Oversee master data management systems and tools, supporting broader data governance efforts to drive data quality
  • Manage, plan, and maintain significant budget cycles for technology projects, as well as ongoing licenses and support/maintenance contracts for the application portfolio
  • Collaborate with IT management and liaisons in the planning and implementation of corporate production applications, systems, and core infrastructure
  • Monitor, maintain, administer, and support enterprise application software to meet or exceed service level agreements
  • Create and maintain documentation for application configurations, services, network mapping, processes, security, and compliance configurations
  • Participate and help develop, implement, and maintain policies, procedures, and associated training plans for the administration and usage of core enterprise applications and systems
  • Participate and assist in the planning of corporate disaster recovery exercises and drills
  • Oversee installation, configuration, maintenance, and troubleshooting of application software, infrastructure, and peripheral devices
  • Analyze and resolve problems with all Enterprise Applications
  • Provide for the support and troubleshooting of corporate enterprise applications and systems as required
  • Configure and deploy application software and systems to ensure smooth and reliable operation to fulfill business objectives and processes
  • Monitor systems performance and troubleshoot problem areas as required
  • Provide technical support, primarily for GxP-validated computer systems
  • Ensure systems are validated in accordance with regulatory requirements, such as 21 CFR Part 11
  • Maintain good working relationships with selected business units and vendors
  • Provide IT-specific guidance to departments for outsourcing needs
  • Assume IT lead for installation, validation, troubleshooting, and management of hardware and software for all R&D, G&A, and Discovery systems
  • Responsible for application user and group administration
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies. They collaborate with larger firms, like Gilead Sciences, to co-develop therapies, which helps them secure funding and speed up the development process. Their goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

IPO

Total Funding

$537M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

8%

1 year growth

21%

2 year growth

86%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tango's recent $80 million private placement financing strengthens their financial position and supports ongoing R&D efforts.
  • The company's ability to secure Orphan Drug Designation and Fast Track Designation for their therapies highlights their potential to bring innovative treatments to market quickly.
  • Participation in high-profile investor conferences and scientific meetings enhances Tango's visibility and credibility in the biotech community.

What critics are saying

  • The discontinuation of the TNG348 program due to liver toxicity raises concerns about the safety and viability of their drug candidates.
  • The highly competitive oncology market requires continuous innovation and successful clinical trials to maintain a leading position.

What makes Tango Therapeutics unique

  • Tango Therapeutics leverages the principle of synthetic lethality to develop cancer treatments, a unique approach that specifically targets cancer cells while sparing healthy ones.
  • Their strategic collaborations with larger pharmaceutical companies like Gilead Sciences provide financial support and accelerate the development and commercialization of their therapies.
  • Tango's robust pipeline and focus on precision oncology, including targeting MTAP-deleted solid tumors and BRCA1/2 mutations, set them apart in the oncology market.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE